EXPRESS: CGRP Expression and Signaling Sensitization in a Mouse Model of Chronic Oxaliplatin-Induced Peripheral Neuropathy
Molecular Pain · 2026
DOI: 10.1177/17448069261432028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2026. Verfasst von Junwei Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Oxaliplatin, Peripheral Nervous System Diseases, Signal Transduction. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting side effect of oxaliplatin treatment, yet its molecular mechanisms remain incompletely understood. Calcitonin gene-related peptide alpha (CGRPα, encoded by Calca) is a neuropeptide implicated in several chronic pain conditions and has been proposed to mediate CIPN-related hypersensitivity. Here, we investigated the role of CGRPα in a mouse model of chronic oxaliplatin-induced neuropathy. Mice treated with oxaliplatin over eight weeks developed cold allodynia and reduced sensory nerve conduction velocity, recapitulating hallmark clinical symptoms of chronic CIPN. However, contrary to expectations, we observed no increase in Calca mRNA expression or protein levels in the dorsal root ganglia (DRG) of male mice and a significant decrease in female mice. The proportion of CGRP-expressing neurons remained unchanged. RNA-seq revealed a two-fold upregulation of Ramp1, a subunit of the CGRP receptor complex. These results suggest that CGRPα signaling may be enhanced not by increased peptide expression, but rather by increased calcium-dependent release from existing neurons and increased CGRP receptor sensitization. This is consistent with known effects of oxaliplatin-induced oxidative stress, which can activate TRPA1 channels and promote calcium-dependent vesicular release of neuropeptides. Although additional validation of this model is needed, our data support a revised rationale of CGRP involvement in CIPN based on sensitization and neuropeptide release, rather than upregulation, and point to TRPA1–CGRP interactions as a potential therapeutic target in oxaliplatin-induced neuropathic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
- Institute of Materials Science & Engineering, Washington University, St. Louis, MO, USA.
- Paul L. Foster School of Medicine, El Paso, TX, USA.
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Mikhail Y Berezin
Förderung
- NCATS NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
- NIH/NCI
- NIH/NINDS
Zitieren
APA
Du, J., Sudlow, L. C., Johnson, M. H., Satish, K., Villagomez, A., Hu, H., & Berezin, M. Y. (2026). EXPRESS: CGRP Expression and Signaling Sensitization in a Mouse Model of Chronic Oxaliplatin-Induced Peripheral Neuropathy. Molecular Pain. https://doi.org/10.1177/17448069261432028
Vancouver
Du J, Sudlow LC, Johnson MH, Satish K, Villagomez A, Hu H, et al. EXPRESS: CGRP Expression and Signaling Sensitization in a Mouse Model of Chronic Oxaliplatin-Induced Peripheral Neuropathy. Molecular Pain. 2026. doi:10.1177/17448069261432028
BibTeX
@article{Du2026,
author = {Du, Junwei and Sudlow, Leland C and Johnson, Margaret H and Satish, Kanishk and Villagomez, Abraham and Hu, Hongzhen and Berezin, Mikhail Y},
title = {EXPRESS: CGRP Expression and Signaling Sensitization in a Mouse Model of Chronic Oxaliplatin-Induced Peripheral Neuropathy},
journal = {Molecular Pain},
year = {2026},
doi = {10.1177/17448069261432028}
}
EUVIMED